MEDICAL SERVICES & DEVICES
reporting to public health emergencies. By implementing proactive reporting requirements and expanding funding for supply chain programmes, the FDA hopes to prevent shortages before they occur.
Congress has allocated additional resources to the CDRH in recent years, but more funding is needed to address systemic vulnerabilities. The agency continues to advocate for a strengthened supply chain programme that would support early detection of disruptions and facilitate the development of risk mitigation strategies.
Broader collaboration with international partners, healthcare providers and manufacturers will also be critical. Leveraging data and communication channels to anticipate risks and improve responsiveness can create a more resilient system that ensures patients, particularly the youngest and most vulnerable, receive uninterrupted care.
As the FDA continues to prioritise supply chain resilience, its commitment to safeguarding patient health remains steadfast. Michelle reinforces this:“ The FDA recognises that early awareness of supply chain disruptions is essential to mitigating the impacts of potential medical device shortages on patient care and protecting the public health.”
By addressing these challenges, the US has the opportunity to build a supply chain that protects patients, supports healthcare providers and ensures critical devices are available when they are most needed.
healthcare-digital. com 93